Company news

Shanghai Shen Lian Biomedical Corporation Class A (SSE:688098) news

Shanghai Shen Lian Biomedical Corporation Class A news releases on 6ix. Latest, Sep 21, 2026: "Shanghai Shen Lian Biomedical Corporation"Announcement…

Shanghai Shen Lian Biomedical Corporation Class A (SSE:688098) news

Press releases & updates

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of the Achievement of Primary Endpoint in the Phase II Clinical Trial of UB-221 for the Treatment of Chronic Spontaneous Urticaria

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of the Amendment to the Collaborative Development Contract for the Multivalent Combination Vaccine Project

"Shanghai Shen Lian Biomedical Corporation"Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"Shanghai Shen Lian Biomedical Corporation"Announcement on Appointment of Deputy General Manager

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Approval of the Veterinary Drug Product Approval Number for the Bivalent Synthetic Peptide Vaccine against Swine Foot-and-Mouth Disease Types O and SAT1

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Obtaining the Approval for Veterinary Drug Product Approval Number

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Approval of Veterinary Drugs Containing SAT 1 Foot-and-Mouth Disease Vaccine

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of Obtaining the Approval Document for a Veterinary Drug Product

Announcement on Voluntary Disclosure of Approval Numbers for Veterinary Drug Products

Announcement on the Completion of Non-Trade Transfer under the 2026 Employee Stock Ownership Plan

Announcement on Resolutions of the 1st Holders' Meeting for 2026 Employee Stock Ownership Plan

Announcement on Resolutions of the 2025 Annual General Meeting

Report for Q1 2026

Announcement on Voluntary Disclosure of the Company Re-certified as High-tech Enterprise

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Preliminary Earnings Estimate for 2025

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Equity Change of Shareholder with Over 5% Shares Reaching 1% Scale, Completion of Shareholding Reduction Plan and Results of Shares Sold

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Earnings Preannouncement for 2025

Announcement on Renewing Engagement of Accounting Firm

Indicative Announcement on Termination of Shareholders’ Acting-in-Concert Relationship and the Change Reaching an Integer Multiple of 5%

Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 5%

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on the Capital Increase and Share Expansion of an Associate Company to Introduce Strategic Investors, and on the Company’s Proposed Acquisition of Controlling Stake in the Associate Company and Signing of the Acquisition Framework Agreement and Related Party Transaction

Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Attending the 2025 Semi-annual SSE STAR Market Innovative Drug Industry Collective Performance Briefing

Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock Company

Special Report on Deposit and Use of Raised Funds in January-June 2025

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on the Signing of a Cooperative Development Agreement for Multivalent Vaccine Projects with Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences

Announcement on Voluntary Disclosure of Registration Approval for New Veterinary Drug Products

Announcement on Voluntary Disclosure of Approval Numbers for Approved Veterinary Drug Products

Announcement on Implementation Results of Share Repurchase and Share Changes

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Attending the Collective Annual Report Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025 and Convening the Q1 2025 Report Performance Briefing

Announcement on Progress in Repurchasing Shares through Call Auction

2024 Annual Report

Announcement on Voluntary Disclosure of Passing GCP Supervision and Inspection for Veterinary Drugs by Ministry of Agriculture and Rural Affairs (MOA)

Announcement on Preliminary Earnings Estimate for 2024

Announcement on the 1st Extraordinary General Meeting in 2025

Announcement on Joint Investment and Related Party Transactions of Wholly-owned Subsidiary

Announcement on Annual Provision for Asset Impairment in 2024

Announcement on Resolution of the 1st Meeting of 4th Board of Supervisors

Announcement on Initially Repurchasing Shares Through Call Auction

Announcement on Appointment of Accounting Firm

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Restrictions Concerning Share Repurchase

Announcement on Resolution of the 15th Meeting of 3rd Board of Directors

Announcement on the Proposal of One of the Actual Controllers and Chairman to Repurchase Shares